Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$84.950.00%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put CRNX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 0% on a typical day and fell roughly 42% in its worst 12-month stretch.
View RiskCRNX's growth trajectory relies on maintaining its recent revenue momentum. Revenue grew 243% year over year, and the last quarter beat expectations. It trades at 242× price-to-sales versus a peer median of 12×. This suggests the price is roughly in line with the growth we forecast. A specific risk is the 25% probability of a miss in the next quarter. Peer multiples imply a price about 20% above where it trades. This read is provisional.
Trailing returns as of 2026-09-02. CRNX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering CRNX (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for CRNX in the last 4 months.
Continue this research
Compare CRNX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CRNX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CRNX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-02. EPS is implied from price ÷ P/E. Not investment advice.
Current $84.95
The last 12 months of price, then the range of analyst 12-month targets from today’s $84.95.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.